Follow the Money: The Manufactured Panic Over 7-OH
Imagine discovering a compound that is quietly helping thousands of Americans survive the deadliest fentanyl crisis in history, only to watch the very people who claim to advocate for you try to ban it.
This isn’t a hypothetical. It’s the current reality of 7-hydroxymitragynine (7-OH), a naturally occurring alkaloid found within the kratom plant.
In July of 2025, the FDA held a press conference to alert the public to a supposedly alarming new health threat, even suggesting the DEA classify 7-OH as a Schedule 1 substance. For an agency historically hostile to natural alternatives, the move wasn’t surprising. What is surprising– and deeply troubling– is who is standing shoulder-to-shoulder with them. The American Kratom Association (AKA) and the Global Kratom Coalition (GKC), organizations built on the promise of protecting consumer access, have joined the crusade to criminalize it.
To understand why an advocacy group would lobby to ban a derivative of the very plant they defend, you have to follow the money. This isn’t a public health crusade. It is a textbook case of corporate protectionism masquerading as public safety.
The Evolution of the Market
For years, the traditional kratom industry thrived on selling raw, crushed leaf and bulky green powders. But the market evolved. Consumers discovered that 7-OH– which makes up about 2% of the plant’s natural alkaloid profile– could be isolated and concentrated.
The shift was immediate. Consumers overwhelmingly prefer the convenience of a precise 7-OH tablet over choking down several grams of bitter, raw plant matter. A single tablet provides the targeted relief of a mountain of powder.
Ironically, the human body already knows this. When you ingest standard mitragynine, your liver naturally oxidizes and converts roughly 25% to 50% of it directly into 7-OH. The modern manufacturing process simply does outside the body what the liver does inside it, utilizing chemical oxidants to target the molecule’s 7-position.
But instead of adapting to changing consumer preferences, the established kratom industry panicked. They saw a superior, more convenient product threatening their multi-million-dollar kingdom, and they chose to fight progress with political warfare.
The Hypocrisy of the Old Guard
This isn’t the AKA’s first time in the political trenches. In 2016, when the FDA attempted a draconian federal ban on kratom, the AKA led a brilliant, community-driven resistance. They championed the Kratom Consumer Protection Act (KCPA), fought media misinformation, and demanded strict third-party testing and age restrictions. They argued passionately that responsible adults deserved safe access to the plant’s alkaloids.
Now, they have abandoned that philosophy to protect their market share.
Leading this aggressive lobbying campaign is Mac Haddow, the head of the AKA. A former HHS Chief of Staff, Haddow is using his high-level Washington connections to feed lawmakers a false narrative about the dangers of 7-OH. It is a cynical play for political leverage– and one that fits a familiar pattern. In 1987, Haddow served a 90-day prison sentence for the misappropriation of over $55,000 from government and private foundation funds. Decades later, he is once again managing institutional influence, this time to monopolize an industry at the expense of public health.
The Flawed Science and Human Cost
The propaganda being fed to state legislators relies entirely on fear, specifically through unsubstantiated claims of “7-OH fatalities.”
But look closer at the data, and the narrative crumbles. There is not a single recorded, verified death caused by the isolated use of 7-OH alone. Every single fatality cited by opponents involves severe polysubstance use– tragic overdoses involving alcohol, illicit narcotics, or lethal street drugs.
Pharmacologically, 7-OH is remarkably safe. As a partial mu-opioid agonist, it binds to receptors differently than traditional narcotics. Crucially, it does not induce respiratory depression–the respiratory failure that makes drugs like fentanyl so deadly. Furthermore, 7-OH possesses a distinct biological “ceiling effect.” Past a certain point, increasing the dosage does not produce exponentially stronger results, rendering a fatal overdose from the isolated substance effectively impossible.
While lobbyists twist this science to secure bans, real people are paying the price. Nationwide overdose statistics are finally trending downward, and a close examination reveals a direct correlation between this decline and the rising popularity of 7-OH.
No one chooses the living hell of fentanyl addiction. For those desperate to reclaim their lives, 7-OH has emerged as a vital, accessible off-ramp from illicit street drugs. Simultaneously, it serves as a critical lifeline for chronic pain patients who have been completely abandoned by a medical system too terrified of the opioid crisis to prescribe effective analgesics.
A Choice Between Agony and the Street
By weaponizing flawed data and lobbying for criminalization, the AKA and the FDA are forcing America’s most vulnerable citizens into an impossible corner.
If 7-OH is banned, thousands of people dealing with untreated, life-altering agony will face a devastating choice: endure a life of physical torture, risk criminal charges to find a natural alternative, or return to the deadly roulette of the black market, where a single pill pressed with fentanyl kills in minutes.
We cannot allow corporate protectionism and backroom political deals to dictate drug policy during a national epidemic. Lawmakers must look past the expensive, lobbied rhetoric, examine the actual pharmacological data, and protect access to a tool that is quietly saving tens of thousands of lives every single year.
